The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
Tóm tắt
Từ khóa
Tài liệu tham khảo
Colombel, 2008, SONIC: a randomized, double blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy, Gut, 57 Suppl II, A1
Su, 2004, A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease, Gastroenterology, 126, 1257, 10.1053/j.gastro.2004.01.024
Froslie, 2007, Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort, Gastroenterology, 133, 412, 10.1053/j.gastro.2007.05.051
Tung, 2006, A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis, Inflamm Bowel Dis, 12, 1093, 10.1097/01.mib.0000235835.32176.85
Bokemeyer, 2009, Predictive factors for a mild course of Crohn's disease, J Crohn's Colitis, 3, S82, 10.1016/S1873-9946(09)60210-5
Seow, 2008, Budesonide for induction of remission in Crohn's disease, Cochrane Database Syst Rev, 3, CD000296
Greenberg, 1994, Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group, New Engl J Med, 331, 836, 10.1056/NEJM199409293311303
Rutgeerts, 1994, A comparison of budesonide with prednisolone for active Crohn's disease, N Engl J Med, 331, 842, 10.1056/NEJM199409293311304
Gross, 1996, Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group, Eur J Gastroenterol Hepatol, 8, 905
Campieri, 1997, Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group, Gut, 41, 209, 10.1136/gut.41.2.209
Bar-Meir, 1998, Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group, Gastroenterology, 115, 835, 10.1016/S0016-5085(98)70254-9
Thomsen, 1998, A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide–Mesalamine Study Group, New Engl J Med, 339, 370, 10.1056/NEJM199808063390603
Tromm, 2009, Double-blind, double-dummy, randomised, multicentre study to compare the efficacy and safety of oral budesonide (9mg) and oral mesalazine (4.5g) in moderately active Crohn's disease patients, Gastroenterology, 139, 391
Hanauer, 2004, Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials, Clin Gastroenterol Hepatol, 2, 379, 10.1016/S1542-3565(04)00122-3
Benchimol, 2008, Traditional corticosteroids for induction of remission in Crohn's disease, Cochrane Database Syst Rev, 2, CD006792
Ho, 2006, The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort, Aliment Pharmacol Ther, 24, 319, 10.1111/j.1365-2036.2006.02974.x
D'Haens G., Panaccione R., Gassull M., Hanauer S.B., Herfarth H. Hommes D.W., Kamm M.A., Lofberg R., Quary A., Sands B., Sood A., Watermeyer G., Sandborn W.J., Colombel J.F., Travis S.P.L. The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organisation: when to start, when to stop and what to do in between? Am J Gastroenterol 2010 (in press).
D'Haens, 2008, Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, Lancet, 371, 660, 10.1016/S0140-6736(08)60304-9
Lichtenstein, 2004, Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries, Am J Gastroenterol, 99, 91, 10.1046/j.1572-0241.2003.04010.x
Feagan, 2008, Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study, Gastroenterology, 135, 1493, 10.1053/j.gastro.2008.07.069
Steinhart, 2002, Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial, Gastroenterology, 123, 33, 10.1053/gast.2002.34225
Vermeire, 2002, Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease, Am J Gastroenterol, 97, 2357, 10.1111/j.1572-0241.2002.05991.x
Summers, 1979, National co-operative Crohn's disease study group: results of drug treatment, Gastroenterology, 77, 847, 10.1016/0016-5085(79)90385-8
Malchow, 1984, European co-operative Crohn's disease study (ECCDS): results of drug treatment, Gastroenterology, 86, 249, 10.1016/0016-5085(84)90409-8
Sutherland, 1991, Double-blind, placebo-controlled trial of metronidazole in Crohn's disease, Gut, 32, 1071, 10.1136/gut.32.9.1071
Zachos, 2007, Enteral nutritional therapy for inducing remission of Crohn's disease, Cochrane Database Syst Rev, 1, CD000542
Colombel, 2007, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial, Gastroenterology, 132, 52, 10.1053/j.gastro.2006.11.041
Sandborn, 2007, Certolizumab pegol for the treatment of Crohn's disease, New Engl J Med, 357, 228, 10.1056/NEJMoa067594
Regueiro, 2009, Infliximab prevents Crohn's disease recurrence after ileal resection, Gastroenterology, 136, 441, 10.1053/j.gastro.2008.10.051
Munkholm, 1995, Disease activity courses in a regional cohort of Crohn's disease patients, Scand J Gastroenterol, 30, 699, 10.3109/00365529509096316
Turner, 2007, Esophageal, gastric, and duodenal manifestations of IBD and the role of upper endoscopy in IBD diagnosis, Curr Gastroenterol Rep, 9, 475, 10.1007/s11894-007-0062-8
Jess, 2002, Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark, Gastroenterology, 122, 1808, 10.1053/gast.2002.33632
Tremaine, 2003, Gastroduodenal Crohn's disease: medical management, Inflamm Bowel Dis, 9, 127, 10.1097/00054725-200303000-00008
Kwan, 2007, Esophageal Crohn's disease treated successfully with adalimumab, Inflamm Bowel Dis, 13, 639, 10.1002/ibd.20103
Sutherland, 1990, Effect of cigarette smoking on recurrence of Crohn's disease, Gastroenterology, 98, 1123, 10.1016/0016-5085(90)90324-T
Duricová, 2009, Overall and cause-specific mortality in Crohn's disease: A meta-analysis of population-based studies, Inflamm Bowel Dis
Beaugerie, 2006, Predictors of Crohn's disease, Gastroenterology, 130, 650, 10.1053/j.gastro.2005.12.019
Seksik, 2007, Validation of predictors of 5-year disabling CD in a population-based cohort from Olmsted County, Minnesota 1983–1996, Gastroenterology, 132, A-17
Loly, 2008, Predictors of severe Crohn's disease, Scand J Gastroenterol, 43, 948, 10.1080/00365520801957149
Cassinnotti, 2009, Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review, Inflamm Bowel Dis, 15, 1264, 10.1002/ibd.20899
Feagan, 2008, A randomized, placebo-controlled study to evaluate the efficacy of infliximab in combination with methotrexate for the long-term treatment of Crohn's disease, Gastroenterology, 134
Hanauer, 2003, Crohn's disease: step up or top down therapy, Best Pract Res Clin Gastroenterol, 17, 131, 10.1053/bega.2003.0361
Tremaine, 1994, A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis, J Clin Gastroenterol, 19, 278, 10.1097/00004836-199412000-00003
Singleton, 1993, Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial, Gastroenterology, 104, 1293, 10.1016/0016-5085(93)90337-C
Feagan, 2004, Editorial: 5-ASA therapy for active Crohn's disease: old friends, old data and a new conclusion, Clin Gastroenterol Hepatol, 2, 376, 10.1016/S1542-3565(04)00121-1
Ransford, 2002, Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines, Gut, 51, 536, 10.1136/gut.51.4.536
Loftus, 2004, Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis, Aliment Pharmacol Ther, 19, 179, 10.1111/j.0269-2813.2004.01827.x
van Staa, 2004, 5-aminosalicylic acids and the risk of renal disease: a large British epidemiological study, Gastroenterology, 126, 1733, 10.1053/j.gastro.2004.03.016
Sutherland, 1997, A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group, Gastroenterology, 112, 1069, 10.1016/S0016-5085(97)70117-3
Ursing, 1982, A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden, Gastroenterology, 83, 550, 10.1016/S0016-5085(82)80189-3
Colombel, 1999, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease, Am J Gastroenterol, 94, 674, 10.1111/j.1572-0241.1999.935_q.x
Prantera, 1996, An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin, Am J Gastroenterol, 91, 328
Borgaonkar, 2000, A meta-analysis of anti-mycobacterial therapy for Crohn's disease, Am J Gastroenterol, 95, 725, 10.1111/j.1572-0241.2000.01842.x
Selby, 2007, Crotty B Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease, Gastroenterology, 132, 2313, 10.1053/j.gastro.2007.03.031
Otley, 2005, Budesonide for induction of remission in Crohn's disease, Cochrane Database Syst Rev, CD000296
Steinhart, 2003, Corticosteroids for maintaining remission of Crohn's disease, Cochrane Database Syst Rev, CD000301
Schoon, 2005, Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease, Clin Gastroenterol Hepatol, 3, 110, 10.1016/S1542-3565(04)00662-7
Aberra, 2003, Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients, Gastroenterology, 125, 320, 10.1016/S0016-5085(03)00883-7
Lichtenstein, 2006, Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry, Clin Gastroenterol Hepatol, 4, 621, 10.1016/j.cgh.2006.03.002
Toruner, 2008, Risk factors for opportunistic infections in patients with inflammatory bowel disease, Gastroenterology, 134, 929, 10.1053/j.gastro.2008.01.012
Fidder, 2009, Long term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study, Gut, 58, 501, 10.1136/gut.2008.163642
2000, Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease, Gut, 46, i1-8
Targan, 1997, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group, N Engl J Med, 337, 1029, 10.1056/NEJM199710093371502
Schnitzler, 2009, Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort, Gut, 58, 492, 10.1136/gut.2008.155812
Hanauer, 2006, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial, Gastroenterology, 130, 323, 10.1053/j.gastro.2005.11.030
Sandborn, 2007, Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial, Ann Intern Med., 146, 829, 10.7326/0003-4819-146-12-200706190-00159
Rutgeerts, 2009, Adalimumab induces and maintains mucosal healing in patients with moderate to severe Crohn's disease. First results of the EXTEND trial, Gastroenterology, 136, A116, 10.1016/S0016-5085(09)60520-5
Schreiber, 2005, CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease, Gastroenterology, 129, 807, 10.1053/j.gastro.2005.06.064
Colombel, 2008, Endoscopic mucosal improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the MUSIC clinical trial, Am J Gastroenterol, 103, A1107, 10.14309/00000434-200809001-01107
Rutgeerts, 2004, Optimising anti-TNF treatment in inflammatory bowel disease, Gastroenterology, 126, 1593, 10.1053/j.gastro.2004.02.070
Colombel, 2004, The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients, Gastroenterology, 126, 19, 10.1053/j.gastro.2003.10.047
Ljung, 2004, Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County, Gut, 53, 849-53.33, 10.1136/gut.2003.018515
Keane, 2001, Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent, N Engl J Med, 345, 1098, 10.1056/NEJMoa011110
Siegel, 2009, Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis, Clin Gastroenterol Hepatol, 7, 874, 10.1016/j.cgh.2009.01.004
Peyrin-Biroulet, 2008, Efficacy and safety of anti-tumor necrosis factor agents in Crohn's disease: a meta-analysis of placebo-controlled trials, Clin Gastroenterol Hepatol, 6, 644, 10.1016/j.cgh.2008.03.014
Hanauer, 2004, Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease, Clin Gastroenterol Hepatol, 2, 542, 10.1016/S1542-3565(04)00238-1
Rutgeerts, 2009, Biological therapies for inflammatory bowel diseases, Gastroenterology, 136, 1182, 10.1053/j.gastro.2009.02.001
Sandborn, 2005, Natalizumab induction and maintenance therapy for Crohn's disease, N Engl J Med, 353, 1912, 10.1056/NEJMoa043335
Targan, 2007, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial, Gastroenterology, 132, 1672, 10.1053/j.gastro.2007.03.024
Hommes, 2004, Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe crohn's disease, Gastroenterology, 127, 332, 10.1053/j.gastro.2004.05.011
Reinisch, 2006, A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanized anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease, Gut, 55, 1138, 10.1136/gut.2005.079434
Mannon, 2004, Anti-interleukin-12 antibody for active Crohn's disease, N Engl J Med, 351, 2069, 10.1056/NEJMoa033402
Sandborn, 2008, Ustekinumab Crohn's Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease, Gastroenterology, 135, 1130, 10.1053/j.gastro.2008.07.014
Ito, 2004, A pilot randomised trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease, Gastroenterology, 126, 989, 10.1053/j.gastro.2004.01.012
Braat, 2005, Interleukin-10 producing Lactococcus lactis for the treatment of Crohn's disease, Gastroenterology, 128, A-104
Tiede, 2003, CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes, J Clin Invest, 111, 1133, 10.1172/JCI16432
Sandborn, 2000, Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease, Cochrane Database Syst Rev, CD000545
Sandborn, 1999, Lack of effect of intravenous administration on time to respond to azathiorpine for steroid-treated Crohn's disease. North American Azathioprine Study Group, Gastroenterology, 117, 527, 10.1016/S0016-5085(99)70445-2
Feagan, 1995, Methotrexate in the treatment of Crohn's disease, N Engl J Med, 332, 292, 10.1056/NEJM199502023320503
Alfadhli, 2003, Methotrexate for induction of remission in refractory Crohn's disease (Cochrane Review), Cochrane Database Syst Rev, CD003459
Fraser, 2003, Methotrexate: first or second-line immunomodulator?, Eur J Gastroenterol Hepatol, 15, 225, 10.1097/00042737-200303000-00003
Feagan, 2000, A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators, N Engl J Med, 342, 1627, 10.1056/NEJM200006013422202
Kurnik, 2003, Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease, Aliment Pharmacol Ther, 18, 57, 10.1046/j.1365-2036.2003.01614.x
Hamilton, 1997, Why intramuscular dosing may be more efficacious than oral dosing in patients with rheumatoid arthritis, Br J Rheumatol, 36, 86, 10.1093/rheumatology/36.1.86
Whittle, 2004, Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review, Rheumatology (Oxford), 43, 267, 10.1093/rheumatology/keh088
Te, 2000, Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease, Am J Gastroenterol, 95, 3150, 10.1111/j.1572-0241.2000.03287.x
Brynskov, 1989, A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease, N Engl J Med, 321, 845, 10.1056/NEJM198909283211301
Feagan, 1994, Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators, N Engl J Med, 330, 1846, 10.1056/NEJM199406303302602
Jewell, 1994, Oral cyclosporine for chronic active Crohn's disease: a multi-centre controlled trial, Eur J Gastroenterol Hepatol, 6, 499, 10.1097/00042737-199406000-00009
Stange, 1995, European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group, Gastroenterology, 109, 774, 10.1016/0016-5085(95)90384-4
Hermida-Rodriguez, 1999, High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease, Hepatogastroenterology, 46, 2265
Santos, 1995, Intravenous cyclosporine for steroid-refractory attacks of Crohn's disease. Short- and long-term results, J Clin Gastroenterol, 20, 207, 10.1097/00004836-199504000-00009
Egan, 1998, Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine, Am J Gastroenterol, 93, 442, 10.1111/j.1572-0241.1998.00442.x
Ierardi, 2001, Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance, Aliment Pharmacol Ther, 15, 371, 10.1046/j.1365-2036.2001.00938.x
Fellermann, 1998, Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506), Am J Gastroenterol, 93, 1860, 10.1111/j.1572-0241.1998.539_g.x
Sandborn, 1997, Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease, Am J Gastroenterol, 92, 876
Zachos, 2001, Enteral nutritional therapy for inducing remission of Crohn's disease, Cochrane Database Syst Rev, CD000542
Gassull, 2001, Nutrition in inflammatory bowel disease, Curr Opin Nutr Metab Care, 4, 561, 10.1097/00075197-200111000-00018
Johnson, 2003, Review article: smoking cessation as primary therapy to modify the course of Crohn's disease, Aliment Pharmacol Ther, 15, 401
Cosnes, 1996, Effects of cigarette smoking on the long-term course of Crohn's disease, Gastroenterology, 110, 424, 10.1053/gast.1996.v110.pm8566589
Breuer-Katschinski, 1996, Effect of cigarette smoking on the course of Crohn's disease, Eur J Gastroenterol Hepatol, 8, 225, 10.1097/00042737-199603000-00007
Nagy, 2008, Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease, World J Gastroenterol, 14, 4342, 10.3748/wjg.14.4342
Candy, 1995, A controlled double blind study of azathioprine in the management of Crohn's disease, Gut, 37, 674, 10.1136/gut.37.5.674
Hanauer, 2002, Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial, Lancet, 359, 1541, 10.1016/S0140-6736(02)08512-4
Lémann, 2006, Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial, Gastroenterology, 130, 1054, 10.1053/j.gastro.2006.02.014
Lémann, 2005, A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine, Gastroenterology, 128, 1812, 10.1053/j.gastro.2005.03.031
Treton, 2009, Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse, Clin Gastroenterol Hepatol, 7, 80, 10.1016/j.cgh.2008.08.028
Kandiel, 2005, Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine, Gut, 54, 1121, 10.1136/gut.2004.049460
Beaugerie, 2009, Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study, Lancet, 374, 1617, 10.1016/S0140-6736(09)61302-7
Lémann, 2000, Methotrexate in Crohn's disease: long-term efficacy and toxicity, Am J Gastroenterol, 95, 1730
Fraser, 2002, The efficacy of methotrexate for maintaining remission in inflammatory bowel disease, Aliment Pharmacol Ther, 16, 693, 10.1046/j.1365-2036.2002.01227.x
Louis, 2008, Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: interim analysis of a prospective cohort study, Gut, 57, A66
1990, Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease, Aliment Pharmacol Ther, 4, 55, 10.1111/j.1365-2036.1990.tb00449.x
Bresci, 1991, 5-aminosalicylic acid in the prevention of relapses of Crohn's disease in remission: a long-term study, Int J Clin Pharmacol Res, 11, 200
Brignola, 1992, Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease, Dig Dis Sci, 37, 29, 10.1007/BF01308338
Prantera, 1992, Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group, Gastroenterology, 103, 363, 10.1016/0016-5085(92)90822-G
Gendre, 1993, Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID), Gastroenterology, 104, 435, 10.1016/0016-5085(93)90411-5
Arber, 1995, A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission, J Clin Gastroenterol, 20, 203, 10.1097/00004836-199504000-00008
Thomson, 1995, Mesalazine (Mesasal/Claversal) 1.5g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease, Aliment Pharmacol Ther, 9, 673, 10.1111/j.1365-2036.1995.tb00438.x
Modigliani, 1996, Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives, Gastroenterology, 110, 688, 10.1053/gast.1996.v110.pm8608877
de Franchis, 1997, Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease, Aliment Pharmacol Ther, 11, 845, 10.1046/j.1365-2036.1997.00212.x
Sutherland LR, Steinhart AH. Mesalazine as a maintenance treatment in Crohn's.
Mahmud, 2001, Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study, Gut, 49, 552, 10.1136/gut.49.4.552
Steinhart, 1994, Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis, Am J Gastroenterol, 89, 2116
Messori, 1994, Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis, Am J Gastroenterol, 89, 692
Camma, 1997, Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables, Gastroenterology, 113, 1465, 10.1053/gast.1997.v113.pm9352848
Akobeng, 2007, Enteral nutrition for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, 3, CD005984
Steinhart A.H., Forbes A., Mills E.C., et al. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 25, 1389–1399.
Elliott, 1982, Sulphadoxine–pyrimethamine therapy in Crohn's disease, Digestion, 23, 132, 10.1159/000198703
Shaffer, 1984, Controlled trial of rifampicin and ethambutol in Crohn's disease, Gut, 25, 203, 10.1136/gut.25.2.203
Basilisco, 1989, Controlled trial of rifabutin in Crohn's disease, Curr Therap Res, 46, 245
Borgaonkar, 2001, Anti-tuberculous therapy for maintaining remission of Crohn's disease (Cochrane Review), vol. 4
Afdhal, 1991, Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo, Dig Dis Sci, 36, 449, 10.1007/BF01298873
Prantera, 1994, Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen, Am J Gastroenterol, 89, 513
Swift, 1994, Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease, Gut, 35, 363, 10.1136/gut.35.3.363
Goodgame, 2001, Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease, Aliment Pharmacol Ther, 15, 1861, 10.1046/j.1365-2036.2001.01099.x
Borgaonkar M, MacIntosh D, Fardy J, Simms L. Anti-tuberculous therapy for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000;2:CD000299.
Lofberg, 1996, Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study, Gut, 39, 82, 10.1136/gut.39.1.82
Greenberg, 1996, Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group, Gastroenterology, 110, 45, 10.1053/gast.1996.v110.pm8536887
Ferguson, 1998, Oral budesonide as maintenance therapy in Crohn's disease—results of a 12-month study. Global Budesonide Study Group, Aliment Pharmacol Ther, 12, 175, 10.1046/j.1365-2036.1998.00285.x
Gross, 1998, Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group, Gut, 42, 493, 10.1136/gut.42.4.493
Cortot, 2001, Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease, Gut, 48, 186, 10.1136/gut.48.2.186
Hanauer, 2005, Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial, Aliment Pharmacol Ther, 21, 363, 10.1111/j.1365-2036.2005.02338.x
Mantzaris, 2003, Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease, Clin Gastroenterol Hepatol, 1, 122, 10.1053/cgh.2003.50015
Stockbrugger, 2003, Budesonide versus prednisolone in the management of Crohn's disease: a randomized multinational 2-year study, Gastroenterology, 124, A26, 10.1016/S0016-5085(03)80128-2
de Jong, 2007, Maintenance treatment with budesonide 6mg versus 9mg once daily in patients with Crohn's disease in remission, Neth J Med, 65, 339
Green, 2001, Maintenance of Crohn's disease over 12months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules, Aliment Pharmacol Ther, 15, 1331, 10.1046/j.1365-2036.2001.01055.x
Papi, 2000, Budesonide in the treatment of Crohn's disease: a meta-analysis, Aliment Pharmacol Ther, 14, 1419, 10.1046/j.1365-2036.2000.00867.x
Simms, 2001, Budesonide for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, CD002913
Sandborn, 2005, Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials, Am J Gastroenterol, 100, 1780, 10.1111/j.1572-0241.2005.41992.x
Benchimol, 2009, Budesonide formaintenance of remission in Crohn'sdisease, Cochrane Database Syst Rev, 1, CD002913
Cino, 2002, Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy, Am J Gastroenterol, 97, 915, 10.1111/j.1572-0241.2002.05609.x
Lichtenstein, 2009, Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis, Aliment Pharmacol Ther, 29, 643, 10.1111/j.1365-2036.2008.03891.x
Willoughby, 1971, Controlled trial of azathioprine in Crohn's disease, Lancet, ii, 944, 10.1016/S0140-6736(71)90268-6
Rosenberg, 1975, A controlled trial of azathioprine in Crohn's disease, Am J Dig Dis, 20, 721, 10.1007/BF01070829
O'Donoghue, 1978, Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease, Lancet, ii, 955, 10.1016/S0140-6736(78)92524-2
Markowitz, 2000, A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease, Gastroenterology, 119, 895, 10.1053/gast.2000.18144
Pearson, 2000, Azathioprine for maintaining remission of Crohn's disease, Cochrane Database Syst Rev, CD000067
Prefontaine, 2009, Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, 1, CD000067
Reinisch, 2008, A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease, Am J Gastroenterol, 103, 2284, 10.1111/j.1572-0241.2008.02024.x
Dubinsky, 2001, An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy, Inflamm Bowel Dis, 7, 181, 10.1097/00054725-200108000-00001
Bonaz, 2003, Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine, Aliment Pharmacol Ther, 15, 401, 10.1046/j.1365-2036.2003.01683.x
Geller, 2004, Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease, Am J Surg Pathol, 28, 1204, 10.1097/01.pas.0000128665.12063.97
Dubinsky, 2003, 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients, Gastroenterology, 125, 298, 10.1016/S0016-5085(03)00938-7
Seiderer, 2004, Nodular regenerative hyperplasia in IBD patients on 6-thioguanine — a multi-centre safety assessment by MRI and liver biopsy, Gastroenterology, 126, 813
Rulyak, 2003, Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease, J Clin Gastroenterol, 36, 234, 10.1097/00004836-200303000-00010
Ansari, 2008, Further experience with the use of 6-thioguanine in patients with Crohn's disease, Inflamm Bowel Dis., 14, 1399, 10.1002/ibd.20492
Arora, 1999, Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial, Hepatogastroenterology, 46, 1724
Sandborn, 2001, An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial, Gastroenterology, 120, 1330, 10.1053/gast.2001.24042
Rutgeerts, 1999, Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease, Gastroenterology, 117, 761, 10.1016/S0016-5085(99)70332-X
Sandborn, 2004, CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial, Gut, 53, 1485, 10.1136/gut.2003.035253
Schreiber, 2007, Maintenance therapy with certolizumab pegol for Crohn's disease, N Engl J Med, 357, 239, 10.1056/NEJMoa062897
Feagan, 2005, A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease, Aliment Pharmacol Ther, 21, 373, 10.1111/j.1365-2036.2005.02336.x
Sandborn, 2007, Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial, Gut, 56, 1232, 10.1136/gut.2006.106781
Behm, 2009, Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, 1, CD006893
Rutgeerts, 2004, Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease, Gastroenterology, 126, 402, 10.1053/j.gastro.2003.11.014
Baert, 2003, Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease, N Engl J Med, 348, 601, 10.1056/NEJMoa020888
Vermiere, 2007, Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease, Gut, 56, 1226, 10.1136/gut.2006.099978
Van Assche, 2008, Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial, Gastroenterology, 134, 1861, 10.1053/j.gastro.2008.03.004
Mackey, 2007, Hepatosplenic T cell lymphoma associated with infliximab use inyoung patients treated for inflammatory bowel disease, J Pediatr Gastroenterol Nutr, 44, 265, 10.1097/MPG.0b013e31802f6424
Lichtenstein, 2009, Benefits and risks of immunomodulators and maintenance infliximab for IBD: subgroup analyses across four randomized trials, Aliment Pharmacol Ther, 10.1111/j.1365-2036.2009.04027.x
Van Assche, 2005, Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease, N Engl J Med, 353, 362, 10.1056/NEJMoa051586
Peyrin-Biroulet, 2008, Crohn's disease: beyond antagonists of tumour necrosis factor, Lancet, 372, 67, 10.1016/S0140-6736(08)60995-2
Belluzzi, 1996, Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease, N Engl J Med, 334, 1557, 10.1056/NEJM199606133342401
Lorenz-Meyer, 1996, Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group), Scand J Gastroenterol, 31, 778, 10.3109/00365529609010352
Feagan, 2008, Omega-3 free fatty acids for the maintenance of remission inCrohn disease: the EPIC Randomized Controlled Trials, JAMA, 299, 1690, 10.1001/jama.299.14.1690
Romano, 2005, Usefulness of omega-3 fatty acid supplementation in addition to mesalazine inmaintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study, World J Gastroenterol, 11, 7118, 10.3748/wjg.v11.i45.7118
Turner, 2009, Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, 1, CD006320
Verma, 2000, Oral nutritional supplementation is effective in the maintenance of remission in Crohn's disease, Dig Liver Dis, 32, 769, 10.1016/S1590-8658(00)80353-9
Takagi, 2006, Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn's disease: A randomized-controlled trial, Aliment Pharmacol Ther, 24, 1333, 10.1111/j.1365-2036.2006.03120.x
Akobeng, 2005, Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease, Cochrane Database Syst Rev, CD003715
Malchow, 1997, Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?, J Clin Gastroenterol, 25, 653, 10.1097/00004836-199712000-00021
Guslandi, 2000, Saccharomyces boulardii in maintenance treatment of Crohn's disease, Dig Dis Sci, 45, 1462, 10.1023/A:1005588911207
Zocco, 2003, Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease, Gastroenterology, 124, A201, 10.1016/S0016-5085(03)81006-5
Schultz, 2004, Lactobacillus GG in inducing and maintaining remission of Crohn's disease, BMC Gastroenterol., 4, 5, 10.1186/1471-230X-4-5
Bousvaros, 2005, A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease, Inflamm Bowel Dis, 11, 833, 10.1097/01.MIB.0000175905.00212.2c
Rolfe, 2006, Probiotics for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, CD004826
Lerebours, 1994, Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives, Gastroenterology, 107, 357, 10.1016/0016-5085(94)90159-7
Sandborn, 2006, Preliminary data on the use of apheresis in inflammatory bowel disease, Inflamm Bowel Dis, 12, S15, 10.1097/01.MIB.0000195387.26892.22
Oyama, 2005, Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease, Gastroenterology, 128, 552, 10.1053/j.gastro.2004.11.051
Cassinotti, 2008, Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease, Gut, 57, 211, 10.1136/gut.2007.128694
Heuman, 1983, The influence of disease at the margin of resection on the outcome of Crohn's disease, Br J Surg, 70, 519, 10.1002/bjs.1800700904
Graadal, 1994, Crohn disease. Long-term effects of surgical treatment, Tidsskr Nor Laegeforen, 114, 1603
Nordgren, 1994, Long-term follow-up in Crohn's disease. Mortality, morbidity, and functional status, Scand J Gastroenterol, 29, 1122, 10.3109/00365529409094898
Weston, 1996, Ileocolic resection for acute presentation of Crohn's disease of the ileum, Dis Colon Rectum, 39, 841, 10.1007/BF02053980
Kim, 1997, Long-term outcome after ileocecal resection for Crohn's disease, Am Surg, 63, 627
Tromm, 1992, Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease, Scand J Gastroenterol, 27, 774, 10.3109/00365529209011182
Vermeire, 2005, The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases, Nat Clin Pract Gastroenterol Hepatol, 2, 580, 10.1038/ncpgasthep0359
Solem, 2005, Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease, Inflamm Bowel Dis, 11, 707, 10.1097/01.MIB.0000173271.18319.53
Hassan, 2007, Systematic review: endoscopic dilatation in Crohn's disease, Aliment Pharmacol Ther, 26, 1457, 10.1111/j.1365-2036.2007.03532.x
Gervais, 2002, Percutaneous abscess drainage in Crohn disease: technical success and short- and long-term outcomes during 14years, Radiology, 222, 645, 10.1148/radiol.2223010554
Garcia, 2001, Abscesses in Crohn's disease: outcome of medical versus surgical treatment, J Clin Gastroenterol, 32, 409, 10.1097/00004836-200105000-00010
Yamaguchi, 2004, The clinical characteristics and outcome of intraabdominal abscess in Crohn's disease, J Gastroenterol, 39, 441, 10.1007/s00535-003-1317-2
Michelassi, 2004, Side-to-side isoperistaltic strictureplasty in the treatment of extensive Crohn's disease, J Surg Res, 117, 71, 10.1016/j.jss.2003.11.008
Sampietro, 2003, Strictureplasty in the surgical treatment of complicated Crohn's disease, Ann Ital Chir, 74, 659
Tonelli, 2004, Indications and results of side-to-side isoperistaltic strictureplasty in Crohn's disease, Dis Colon Rectum, 47, 494, 10.1007/s10350-003-0084-8
Shatari, 2004, Long strictureplasty is as safe and effective as short strictureplasty in small-bowel Crohn's disease, Colorectal Dis, 6, 438, 10.1111/j.1463-1318.2004.00664.x
Poggioli, 2003, A new model of strictureplasty for multiple and long stenoses in Crohn's ileitis: side-to-side diseased to disease-free anastomosis, Dis Colon Rectum, 46, 127, 10.1007/s10350-004-6508-2
Tichansky, 2000, Strictureplasty for Crohn's disease: meta-analysis, Dis Colon Rectum, 43, 911, 10.1007/BF02237350
Reese, 2007, Strictureplasty vs resection in small bowel Crohn's disease: an evaluation of short-term outcomes and recurrence, Colorectal Dis, 9, 686, 10.1111/j.1463-1318.2006.01114.x
Yamamoto, 2007, Safety and efficacy of strictureplasty for Crohn's disease: a systematic review and meta-analysis, Dis Colon Rectum, 50, 1968, 10.1007/s10350-007-0279-5
Fearnhead, 2006, Long-term follow-up of strictureplasty for Crohn's disease, Br J Surg, 93, 475, 10.1002/bjs.5179
Fichera, 2006, Patterns and operative treatment of recurrent Crohn's disease: a prospective longitudinal study, Surgery, 140, 649, 10.1016/j.surg.2006.07.011
Menon, 2007, Adenocarcinoma of the small bowel arising from a previous strictureplasty for Crohn's disease: report of a case, Dis Colon Rectum, 50, 257, 10.1007/s10350-006-0771-3
Hashemi, 1998, Side-to-side stapled anastomosis may delay recurrence in Crohn's disease, Dis Colon Rectum, 41, 1293, 10.1007/BF02258231
Scarpa, 2004, Role of stapled and hand-sewn anastomoses in recurrence of Crohn's disease, Hepatogastroenterology, 51, 1053
Yamamoto, 1999, Stapled functional end-to-end anastomosis versus sutured end-to-end anastomosis after ileocolonic resection in Crohn disease, Scand J Gastroenterol, 34, 708, 10.1080/003655299750025921
Tersigni, 2003, Does stapled functional end-to-end anastomosis affect recurrence of Crohn's disease after ileocolonic resection?, Hepatogastroenterology, 50, 1422
Scott, 1995, Anastomotic configuration does not affect recurrence of Crohn's disease after ileocolonic resection, Int J Colorectal Dis, 10, 67, 10.1007/BF00341197
Ikeuchi, 2000, Long-term results of stapled and hand-sewn anastomoses in patients with Crohn's disease, Dig Surg, 17, 493, 10.1159/000051946
Simillis, 2007, A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn's disease, Dis Colon Rectum, 50, 1674, 10.1007/s10350-007-9011-8
Benoist, 2003, Laparoscopic ileocecal resection in Crohn's disease: a case-matched comparison with open resection, Surg Endosc, 17, 814, 10.1007/s00464-002-9103-4
Marcello, 2000, Laparoscopic restorative proctocolectomy: case-matched comparative study with open restorative proctocolectomy, Dis Colon Rectum, 43, 604, 10.1007/BF02235570
Tabet, 2001, Laparoscopic versus open bowel resection for Crohn's disease, Can J Gastroenterol, 15, 237, 10.1155/2001/814749
Tan, 2007, Laparoscopic surgery for Crohn's disease: a meta-analysis, Dis Colon Rectum, 50, 576, 10.1007/s10350-006-0855-0
Tilney, 2006, Comparison of laparoscopic and open ileocecal resection for Crohn's disease: a metaanalysis, Surg Endosc, 20, 1036, 10.1007/s00464-005-0500-3
Lesperance, 2009, National trends and outcomes for the surgical therapy of ileocolonic Crohn's disease: a population-based analysis of laparoscopic vs. open approaches, J Gastrointest Surg, 10.1007/s11605-009-0853-3
Milsom, 2001, Prospective, randomized trial comparing laparoscopic vs. conventional surgery for refractory ileocolic Crohn's disease, Dis Colon Rectum, 44, 1, 10.1007/BF02234810
Maartense, 2006, Laparoscopic-assisted versus open ileocolic resection for Crohn's disease: a randomized trial, Ann Surg, 243, 143, 10.1097/01.sla.0000197318.37459.ec
Allan, 1989, Segmental colonic resection is an appropriate operation for short skip lesions due to Crohn's disease in the colon, World J Surg, 13, 611, 10.1007/BF01658882
Eshuis, 2008, Long-term surgical recurrence, morbidity, quality of life, and body image of laparoscopic-assisted vs. open ileocolic resection for Crohn's disease: a comparative study, Dis Colon Rectum, 51, 858, 10.1007/s10350-008-9195-6
Lawes, 2006, Avoidance of laparotomy for recurrent disease is a long-term benefit of laparoscopic resection for Crohn's disease, Br J Surg, 93, 607, 10.1002/bjs.5286
Goyer, 2009, Impact of complex Crohn's disease on the outcome of laparoscopic ileocecal resection: a comparative clinical study in 124 patients, Dis Colon Rectum, 52, 205, 10.1007/DCR.0b013e31819c9c08
Alves, 2005, Factors that predict conversion in 69 consecutive patients undergoing laparoscopic ileocecal resection for Crohn's disease: a prospective study, Dis Colon Rectum, 48, 2302, 10.1007/s10350-005-0190-x
Bernell, 2001, Recurrence after colectomy in Crohn's colitis, Dis Colon Rectum, 44, 647, 10.1007/BF02234559
Yamamoto, 1999, Proctocolectomy is associated with a higher complication rate but carries a lower recurrence rate than total colectomy and ileorectal anastomosis in Crohn colitis, Scand J Gastroenterol, 34, 1212, 10.1080/003655299750024724
Tonelli, 2003, Colorectal Crohn's disease: indications to surgical treatment, Ann Ital Chir, 74, 665
Longo, 1988, Treatment of Crohn's colitis. Segmental or total colectomy?, Arch Surg, 123, 588, 10.1001/archsurg.1988.01400290070011
Andersson, 2002, Segmental resection or subtotal colectomy in Crohn's colitis?, Dis Colon Rectum, 45, 47, 10.1007/s10350-004-6113-4
Morini, 2003, Long-term outcome of endoscopic pneumatic dilatation in Crohn's disease, Dig Liver Dis, 12, 851
Breysem, 1992, Endoscopic balloon dilation of colonic and ileo-colonic Crohn's strictures: long-term results, Gastrointest Endosc, 38, 142, 10.1016/S0016-5107(92)70379-4
Thomas-Gibson, 2003, Colonoscopic balloon dilation of Crohn's strictures: a review of long-term outcomes, Eur J Gastroenterol Hepatol, 15, 485
Broering, 2001, Strictureplasty for large bowel stenosis in Crohn's disease: quality of life after surgical therapy, Int J Colorectal Dis, 16, 81, 10.1007/s003840000278
de Oca, 2003, Long-term results of ileal pouch-anal anastomosis in Crohn's disease, Inflamm Bowel Dis, 9, 171, 10.1097/00054725-200305000-00004
Sagar, 1996, Long-term results of ileal pouch-anal anastomosis in patients with Crohn's disease, Dis Colon Rectum, 39, 893, 10.1007/BF02053988
Handelsman, 1993, Crohn's disease as a contraindication to Kock pouch (continent ileostomy), Dis Colon Rectum, 36, 840, 10.1007/BF02047380
Hyman, 1991, Consequences of ileal pouch-anal anastomosis for Crohn's colitis, Dis Colon Rectum, 34, 653, 10.1007/BF02050345
Mylonakis, 2001, How does pouch construction for a final diagnosis of Crohn's disease compare with ileoproctostomy for established Crohn's proctocolitis?, Dis Colon Rectum, 44, 1137, 10.1007/BF02234634
de Oca, 2003, Long-term results of ileal pouch-anal anastomosis in Crohn's disease, Inflamm Bowel Dis, 9, 171, 10.1097/00054725-200305000-00004
Panis, 1996, Ileal pouch/anal anastomosis for Crohn's disease, Lancet, 347, 854, 10.1016/S0140-6736(96)91344-6
Regimbeau, 2001, Long-term results of ileal pouch-anal anastomosis for colorectal Crohn's disease, Dis Colon Rectum, 44, 769, 10.1007/BF02234693
Reese, 2007, The effect of Crohn's disease on outcomes after restorative proctocolectomy, Dis Colon Rectum, 50, 239, 10.1007/s10350-006-0777-x
Prudhomme, 2006, Causes and outcomes of pouch excision after restorative proctocolectomy, Br J Surg, 93, 82, 10.1002/bjs.5147
Brown, 2005, Crohn's disease and indeterminate colitis and the ileal pouch-anal anastomosis: outcomes and patterns of failure, Dis Colon Rectum, 48, 1542, 10.1007/s10350-005-0059-z
Marchal, 2004, The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study, Aliment Pharmacol Ther, 19, 749, 10.1111/j.1365-2036.2004.01904.x
Colombel, 2004, Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy, Am J Gastroenterol, 99, 878, 10.1111/j.1572-0241.2004.04148.x
Appau, 2008, Use of infliximab within 3months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients, J Gastrointest Surg, 12, 1738, 10.1007/s11605-008-0646-0
Yamamoto, 1999, Stapled functional end-to-end anastomosis versus sutured end-to-end anastomosis after ileocolonic resection in Crohn disease, Scand J Gastroenterol, 34, 708, 10.1080/003655299750025921
Mahadevan, 2002, Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications, Inflamm Bowel Dis, 8, 311, 10.1097/00054725-200209000-00001
Tay, 2003, Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty, Surgery, 34, 565, 10.1016/S0039-6060(03)00298-8
Myrelid, 2004, Immunosuppression for Crohn´s disease is associated with increased frequency of anastomotic complications, Colorectal Dis, 6, 26
Kunitake, 2008, Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications, J Gastrointest Surg, 12, 1730, 10.1007/s11605-008-0630-8
Aratari, 2007, Early versus late surgery for ileo-caecal Crohn's disease, Aliment Pharmacol Ther, 26, 1303, 10.1111/j.1365-2036.2007.03515.x
Eshuis, 2008, Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial), BMC Surg, 8, 15, 10.1186/1471-2482-8-15
Reese, 2008, The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies, Int J Colorectal Dis, 23, 1213, 10.1007/s00384-008-0542-9
Sandborn, 2009, Welcome: a randomized, double-blind, controlled trial comparing certolizumab pegol 400mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate to severe Crohn's Disease with secondary failure to infliximab, Gastroenterology, 136, A47